About DnaJ homolog subfamily B member 1
DnaJ homolog subfamily B member 1 (DNAJB1) is a protein
from Homo sapiens identified by UniProt accession
P25685, 340 residues long.
MolForge cross-references it against 0 known binders and
258 disease associations.
Target properties
| Protein name | DnaJ homolog subfamily B member 1 |
|---|
| UniProt accession | P25685 |
|---|
| Gene | DNAJB1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 340 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (258)
Diseases linked to this target (Open Targets).
- Fibrolamellar Carcinoma · score 0.38
- hepatocellular adenoma · score 0.37
- bile duct adenocarcinoma · score 0.37
- hepatocellular carcinoma · score 0.29
- Hepatoblastoma · score 0.28
- head and neck squamous cell carcinoma · score 0.21
- acute myeloid leukemia · score 0.19
- non-small cell lung carcinoma · score 0.19
- skin squamous cell carcinoma · score 0.19
- melanoma · score 0.19
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P25685-F1 | alphafold | PREDICTED | 82.64 | — |
Amino-acid sequence (340 residues)
MGKDYYQTLG LARGASDEEI KRAYRRQALR YHPDKNKEPG AEEKFKEIAE AYDVLSDPRK REIFDRYGEE GLKGSGPSGG SGGGANGTSF SYTFHGDPHA MFAEFFGGRN PFDTFFGQRN GEEGMDIDDP FSGFPMGMGG FTNVNFGRSR SAQEPARKKQ DPPVTHDLRV SLEEIYSGCT KKMKISHKRL NPDGKSIRNE DKILTIEVKK GWKEGTKITF PKEGDQTSNN IPADIVFVLK DKPHNIFKRD GSDVIYPARI SLREALCGCT VNVPTLDGRT IPVVFKDVIR PGMRRKVPGE GLPLPKTPEK RGDLIIEFEV IFPERIPQTS RTVLEQVLPI
Explore DnaJ homolog subfamily B member 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets